Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • GABAB PAM for cough
  • M4 PAM for schizophrenia & other psychosis
  • ADX71149 for epilepsy
  • GABAB PAM for substance use disorder
  • Dipraglurant for post-stroke sensorimotor recovery
  • mGlu7 NAM for stress related disorders including PTSD
  • mGlu2 NAM for mild neurocognitive disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 02.23
    2011

    Addex Pharmaceuticals 2010 Financial Results

  • 02.18
    2011

    Addex Pharmaceuticals 2010 Financial Results Next Wednesday

  • 12.10
    2010

    Addex Awarded EuropaBio’s Most Innovative SME Award

  • 11.12
    2010

    Addex Highlights Strength of Allosteric Modulation Technology Platform with Multiple Presentations at Society for Neuroscience 2010

  • 09.15
    2010

    Addex Pharmaceuticals Raises CHF20 Million from Biotechnology Value Fund

  • 09.08
    2010

    Addex Awarded Michael J. Fox Foundation Grant for ADX48621 to Treat Levodopa-Induced Dyskinesia in Parkinson’s

  • 09.02
    2010

    Addex Drug Candidate Effective in Alzheimer’s Disease Model

  • 08.25
    2010

    Addex Partner Completes ADX71149 Phase I Program

  • 07.28
    2010

    Addex Pharmaceuticals First Half 2010 Financial Results

  • 07.21
    2010

    Addex First Half 2010 Financial Results Next Wednesday

    Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next

Contact us

If you have any questions please let me know
  • Contact form
2026 © Addex therapeutics